The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

Chromaderm, Inc.

Overview

The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Diabetic Nephropathy

Interventions

LY333531DRUG

Eligibility

Sex: ALLMin age: 30 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes mellitus * Greater than or equal to 30 years of age * Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier. Exclusion Criteria: * Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females * B/P greater than 150 systolic and greater than 90 diastolic * Hemoglobin Alc greater than 11% * Liver Function Tests 2 times upper limit of normal * Poor medical or psychiatric risk.

Locations (15)

Unnamed facility

La Jolla, California, United States

Unnamed facility

Walnut Creek, California, United States

Unnamed facility

Jacksonville, Florida, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.